worldvaccine CONGRESS 2016

Co-located with:

worldveterinary VACCINE CONGRESS 2016

immuneprofiling WORLD CONGRESS 2016

Congress Agenda

Learn. Discover. Network.

10 – 12 October, Fairmont Rey Juan Carlos, Barcelona

The 17th annual World Vaccine Congress is the place where the global vaccine industry meets to discuss commercial and scientific issues around **regulation,** strategy**, manufacturing** and **clinical trials** as well as **respiratory, cancer, emerging diseases, bacterial infections** and **veterinary vaccines.** For more information please visit www.terrapinn.com/conference/world-vaccine-congress-europe

In collaboration with:

For 2016 speaking opportunities please contact the Project Manager, Wing-yun Cheung on:
wing-yun.cheung@terrapinn.com or on + 44 (0)207 7092 1172

worldvaccine CONGRESS 2016

Our Scientific Advisory Board

Dr Rino Rappuoli, Chief Scientist**, GSK Vaccines**

Dr Jerald Sadoff, Senior Advisor to CEO, **Janssen Infectious Diseases and Vaccines**

Prof Albert Osterhaus, Director Research Center for Emerging Infections and Zoonoses (RIZ), **University of Veterinary Medicine Hannover**

Dr Jeffrey Almond, Former Vice President Discovery Research and Development, Sanofi and Visiting Professor**, University of Oxford**

Dr Antu Dey, Senior Director, Research & Development, **International AIDS Vaccine Initiative (IAVI)**

Dr Nathalie Garcon, CEO/CSO**, BIOASTER**

Prof Manuel J T Carrondo, Vice-President, **IBET**

For 2016 speaking opportunities please contact the Project Manager, Wing-yun Cheung on: wing-yun.cheung@terrapinn.com or on + 44 (0)207 7092 1172

worldvaccine CONGRESS 2016

Over 90 total speakers already confirmed include:

Dr Nicholas Jackson, Vice President, Global Head of Research, Sanofi Pasteur
Prof Stefan Kaufmann, Founding Director and Managing Director of the Max Planck Institute for Infection Biology
Dr Michael Washabaugh, Senior Director, MedImmune
Prof Sarah Gilbert, Professor of Vaccinology, Jenner Institute, University of Oxford
Mai-Britt Zocca, CEO and Founder, IO Biotech Aps
Dr Pierre A. Morgon, Chief Executive Officer, AJ Biologics
Dr Sean Tucker, CSO, Vaxart
Dr Miles Carroll, Deputy Director, Head of Research, Department of Heath
XL Lin, Director, Market Development, Esco Group
Dr Stephen Inglis, Director, NIBSC
Dr Ali Harandi, Associate Professor, Lab head, University of Gothenburg
Dr Behazine Combadiere, Director of Research DR2, INSERM
Dr Daniel Zak, Assistant Professor, The Center for Infectious Disease Research
Dr Christian Brander, Research professor, IrsiCaixa & Scientific Director, HIVACAT Program for AIDS Vaccine Research
Dr Antu Dey, Senior Director, Research & Development, International AIDS Vaccine Initiative (IAVI)
Dr Jeffrey Almond, Former Vice President Discovery Research and Development, Sanofi and Visiting Professor, University of Oxford
Prof Albert Osterhaus, Director Research Center for Emerging Infections and Zoonoses (RIZ), University of Veterinary Medicine Hannover
Dr Jerald Sadoff, Senior Advisor CEO, Janssen Infectious Diseases and Vaccines
Dr Rino Rappuoli, Chief Scientist, GSK Vaccines
Dr Jan T Poolman, Head Bacterial Vaccine Discovery and Early Development, Janssen
Dr Cristina Cassetti, Deputy Chief, Virology Branch Division of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Diseases, NIH
Grant E. Pickering, President & CEO, SutroVax Inc.
Dr Cristiana Campa, Head, Quality by Design Integration, GSK Vaccines
Prof Luis Enjuanes, Research Professor and Coronavirus Laboratory Head, CNB-CSIC
In-Kyu Yoon, Deputy Director General of Science, International Vaccine Institute (IVI)
Dr Jeffrey B. Ulmer, Head, Preclinical R&D US, GSK Vaccines
Malika Almansouri, Vaccine Global Regulatory Affairs, Region Expert MENA/Russia-CIS/India, GSK Vaccines
Thomas Breuer, SVP & Chief Medical Officer, GSK Vaccines
Senior representative, hVIVO
Dr Adrian Wildfire, Project Director - Infectious Diseases & Viral Challenge Unit, SGS Life Sciences
Senior representative, Batavia Biosciences
Senior representative, Pall
Michael Ward, Coordinator, Prequalification Team, Essential Medicines and Health Products, WHO
Dr Suresh Jadhav, Executive Director, Serum Institute of India
Dr Derek O'Hagan, Global Head of Vaccine Chemistry and Formulation Research, GSK
Dr Michele Pallaoro, Head, Vaccines & Diagnostics, GSK Vaccines
Dr Dennis Christensen, Head of section, Vaccine Research & Development , Infectious Disease Immunology, Statens Serum Institut

For 2016 speaking opportunities please contact the Project Manager, Wing-yun Cheung on:
wing-yun.cheung@terrapinn.com or on + 44 (0)207 7092 1172

worldvaccine CONGRESS 2016

Day 1 agenda – 10 October 2016

	Plenary Session		
08:50	Chair's opening remarks		
09:00	Plenary Discussion: The threat of the Zika virus – What have we learnt from the Ebola crisis? - What do we know about the pathogenesis of Zika virus infection? - What is the quickest path to a safe and effective vaccine? - What is the response regulatory authorities to vaccine development? - Will a live virus vaccine be safe enough to vaccinate pregnant women? How will governmental agencies and NGO respond to the Zika threat? - What financial assistance can be expected? Dr Line Matthiessen, Head of Unit, Infectious Diseases, Directorate General for Research and Innovation, European Commission Dr Cristina Cassetti, Deputy Chief, Virology Branch Division of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Diseases, NIH Dr Nicholas Jackson, Vice President, Global Head of Research, Sanofi Pasteur Prof Leda Castilho, Professor, Universidade Federal do Rio de Janeiro Dr Elliot Parks, President & CEO, Hawaii Biotech Inc.		
09:40	Providing RSV protection to pre-infants, elderly and maternal patients - Overview of current RSV vaccine candidates - Understanding RSV epidemiology and pathogenesis - Challenges in providing effective and continuous immunity Dr Jerald Sadoff, Senior Advisor to CEO, Janssen Infectious Diseases and Vaccines		
10:10	How are advances in technology and immunotherapy changing the landscape for non-infectious diseases and therapeutic vaccines? - The future of combination cancer immunotherapies with vaccines, checkpoint inhibitors, neoantigens and oncolytic viruses - Cancer therapies are all heading to combinational approaches but how do we fine tune what should be combined and in what order? - How will combinational approaches reduce side effects and replace conventional treatments including chemotherapy? Dr Karin Jooss, Former Head of Cancer Vaccines and Immunopharmacology, Pfizer Inc.		
10:40	Morning break		
	Respiratory Vaccines Track	Therapeutic Vaccines Track	Emerging & Re-emerging diseases
11:40	Chair's opening remarks	Chair's opening remarks Dr Michael G. Hanna, Jr., Founder & Chairman Emeritus Vaccinogen, Inc.	Chair's opening remarks
	Influenza Vaccines	Cancer and Immunotherapy Vaccines	Platform technologies to emerging pathogens
11:45	Presenting a novel universal influenza vaccine: Enhancing the standard of care Dr Harry Kleanthous, Ass. Vice President, Head DIscovery Research North America, Sanofi Pasteur	The paradoxes and consequences of tumour genomic heterogeneity Dr Michael G. Hanna, Jr., Founder & Chairman Emeritus, Vaccinogen, Inc.	Being prepared: Promising new platform technologies applicable for vaccine development against emerging pathogens Prof Sarah Gilbert, Professor of Vaccinology, Jenner Institute, University of Oxford

worldvaccine CONGRESS 2016

12:15	Advances and prospects for universal and broadly cross-reactive vaccines: Are we getting any closer?	The importance of neoantigens selection in cancer immunotherapy - Identifying personalized, therapeutic neo-antigens for individual patients - Using next-generation sequencing and custom bioinformatics Andrew Allen, CEO & Co-Founder, Gritstone Oncology	Update on the Ebola vaccine: Current epidemiological findings and implications for future vaccine use Dr Jayanthi Wolf, Director, MSD
12:45	High titre neutralizing antibodies to influenza after oral tablet immunization: A phase 1, randomized, placebo-controlled trial Dr Sean Tucker, CSO, Vaxart, Inc.	Ph1 results of a new checkpoint inhibitor vaccine against lung and melanoma cancers Mai-Britt Zocca, CEO and Founder, IO Biotech Aps	Using reverse genetics systems to engineer protective vaccine candidates for SARS-CoV and MERS-CoV vaccine design Prof Luis Enjuanes, Research Professor and Coronavirus Laboratory Head, CNB-CSIC
13:00	Universal pandemic and seasonal influenza vaccine design: Directing the antibody repertoire		
13:15	Networking Lunch & Poster Session		
14:45	**RSV Vaccines** Epidemiology of RSV and its significance to eradication	Optimising HPV vaccine: Combinational trials with checkpoint inhibitors Willem-Jan Krebber, Director Operations, ISA pharmaceuticals	Preventing the pandemic potential of MERS-CoV: Updates on research and clinical development In-Kyu Yoon, Deputy Director General of Science, International Vaccine Institute (IVI)
15:15	Bringing a next-gen mAb RSV treatment to the market Dr Mark Esser, Director, Translational Medicine, Infectious Diseases & Vaccines, Medimmune	Safety, immunogenicity and MOA of a novel HPV-cancer immunotherapy: Results of a phase 1 human clinical trial - Showing strong T-cell responses and aggressive tumour regression - Use in combination with other immuno-oncology platforms to develop powerful therapies Dr Frank Bedu-Addo, President and CEO, PDS Biotechnology	Scientific update and global progression of a dengue vaccine reaching endangered populations Dr Nicholas Jackson, Vice President, Global Head of Research, Sanofi Pasteur

worldvaccine CONGRESS 2016

15:45	Providing active and passive immunizations for the young and old against RSV Reserved for GSK Vaccines	Updated clinical progress on Amgen's oncolytic virus-based immunotherapy T-VEC against melanoma - Creating a highly selective and yet potent oncolytic viral vaccine Reserved for Dr Howard Kaufman, Associate Director for Clinical Science & Chief Surgical Officer, Rutgers Cancer Institute of New Jersey	Development of a malaria vaccine: Testing microcyrstalline tyrosine (MCT) and novel adjuvant formulations in combination with VLPs Reserved for Dr Matthew Heath, Manager, Scientific & Technical Affairs, Bencard Adjuvant Systems The journey to producing an effective malaria vaccine – what's next?
16:15	Networking Break		
16:45	The RSV nanoparticle vaccine, two ph3 trial updates on elderly, infant and maternal immunisation	Genetically engineering oncolytic viruses to express a cDNA library derived from normal or tumour tissue, to generate a potent anti-cancer vaccine Professor Alan Melcher, Professor of Clinical Oncology and Biotherapy, Leeds Institute of Cancer & Pathology	Advancing HIV vaccines from bench to clinic - What are the roadblocks characterising next generation vaccines? Dr Antu K. Dey, Senior Director, Research & Development, International AIDS Vaccine Initiative
17:15	Scientific challenges and results on developing a new pertussis vaccine Dr Rino Rappuoli, Chief Scientist, GSK Vaccines*	Optimizing the therapeutic benefit of checkpoint inhibitors and broadening the potential of immunotherapy	Funding status and opportunities for vaccines against emerging diseases Dr Cristina Cassetti, Deputy Chief, Virology Branch Division of Microbiology and Infectious Diseases, National Institute of Allergy and Infectious Diseases, NIH
17:45	Chair closing remarks of day one followed by drinks reception		

worldvaccine CONGRESS 2016

Day 2 agenda – 11 October 2016

	Plenary Session			
09:00	Chair's opening remarks			
09:05	Impact of new vaccine technology across the value chain: The difficulty and the necessity to innovate - The increasing need to protect against infectious diseases, cancer and other chronic conditions - A revolution in the vaccine field: Recent advances in immunology, structural biology, synthetic biology and genomics - Overcoming challenges in controversies in the safety of adjuvants, increasing regulatory complexity, the inadequate methods used to assess the value of novel vaccines, and the resulting industry alienation from future investment Dr Rino Rappuoli, Chief Scientist, GSK Vaccines			
09:35	How to respond to cultural differences whilst still giving max public health: Balancing end-user acceptability with industrial and regulatory feasibility - Acceptability by the end user and how the industry could and should partner with the authorities to ensure that the targeted coverage rates are reached - Anchoring the manufacturing of vaccines in processes that are increasingly devoid of components of animal origin, ideally by design Dr Pierre A. Morgon, Chief Executive Officer, AJ Biologics			
10:05	Joint discussions: Vaccines manufacturing complexity and regulatory hurdles - WHO update on new Post Approval Change guidelines - Industry comment on the new for regulatory convergence - Authority viewpoint on vaccines complexity Dr Stephen Cook, VP, Vaccine Global Regulatory Affairs; Head of International Region (EMAP / Japan / WHO), GSK Vaccines & representing IFPMA Dr DianLiang Lei, Scientist, Department of Essential Medicines and Health Products (EMP), World Health Organization (WHO) Dr Heidi Meyer, Deputy Head of the Department of Viral vaccines, Paul-Ehrlich-Institut, Germany Dr Suresh Jadhav, Executive Director, Serum Institute of India			
11:00	Morning break			
12:00	Interactive Roundtables *Choose your roundtable session and explore a range of topical issues that can be discussed with other though leaders at a more interactive basis:* *To lead a table or for more information on other topics contact the Project Manager Wing-yun Cheung on Wing-yun.Cheung@terrapinn.com*			
	Promoting a one health research ethos by bringing veterinary and medical scientists together Prof Albert Osterhaus, Director Research Center for Emerging Infections and Zoonoses (RIZ), University of	*Assurance of supply of single-use technologies, including a case study about a pandemic situation* Senior representative, Sartorius	*Regulatory aspects of adjuvants in manufacturing and use* Dr Adrian Wildfire, Project Director - Infectious Diseases & Viral Challenge Unit, SGS Life Sciences	*What's the global strategy in responding to infectious diseases? Combined efforts and differences between Europe and the US*

worldvaccine CONGRESS 2016

	Veterinary Medicine Hannover			
	From surrogate markers to predictive biomarkers of vaccine efficacy: How realistic is it to enhance the blood markers beyond serum antibody? Dr Ali M. Harandi, Lab head, Dpt of Microbiology & Immunology, University of Gothenburg	*Developing improved analytical testing for next-generation vaccines* Dr Cristiana Campa, Head, Quality by Design Integration, GSK Vaccines	*Designing effective processes to enable scalability of vaccine products*	*Vaccine delivery: How to increase efficacy of vaccines, and the challenges from moving to therapeutic vaccines versus prophylactic* Kirsty Gapp, M.T.S Business Development Manager, 3M Healthcare
13:00	Networking Lunch & **Poster Session**			
	New Vaccine Technology & Discovery	**Pre-clinical to Clinical Development**	**Vaccine Bioprocessing**	
14:30	Chair's opening remarks Dr Jeffrey Almond, Former Vice President Discovery Research and Development, Sanofi and Visiting Professor, University of Oxford	Chair's opening remarks	Chair's opening remarks Dr Antu Dey, Senior Director, Research & Development, International AIDS Vaccine Initiative (IAVI)	
	Showcasing New Technology	**Predicting Clinical Outcome**	**Formulation and Bioprocessing**	
14:35	Technology Showcase 1 Next Generation Conjugate Vaccines: How can cell-free protein synthesis permit high-fidelity conjugation to enhance immunogenicity & expand serotype coverage? Grant E. Pickering, President & CEO, SutroVax Inc.	Pre-clinical to clinical vaccine interphase R&D interphase - Animal models and applications to immune profiling of survivors Dr Miles Carroll, Deputy Director, Head of Research, Department of Heath	Physio/chemical analysis to solve the stabilisation challenges in glycoconjugate vaccines Dr Michele Pallaoro, Head, Vaccines & Diagnostics, GSK Vaccines	
14:50	Technology Showcase 2 Introducing a Multiple Antigen Presenting System – Enabling high affinity binding of protective polysaccharides and proteins in a single vaccine Dr Richard Malley, Scientific Founder & CSO, Affinivax			
15:05	Technology Showcase 3 The ability of modified mRNA to express viral antigens *in vivo* and to induce robust immune responses	Developing an integrated and streamlined biomarker development plan	Stabilizing formulations for recombinant viruses - Techniques in stabilising viral formulations without impacting the structural	

worldvaccine CONGRESS 2016

	Dr Giuseppe Ciaramella, Chief Scientific Officer, Valera, A Moderna Venture	- Exploring biomarkers to enable or accelerate clinical development	appearance of the lyophilized product - Antigen-adjuvant compositions and methods
15:20	Technology Showcase 4 **Developing entirely novel protein constructs from RNA for cancer therapy** Dr Mustafa Diken, Deputy Vice President of Immunotherapies and Preclinical Research, Biontech RNA Pharmaceuticals GmbH		
15:35	Technology Showcase 5 **Developing a nanoparticle vaccine system**	**Vaccines and Viral Challenge Agents – What's the difference?** - Stability requirements, excipients and manufacture all differ as does the final products characteristics, outcomes and inoculation timing Dr Adrian Wildfire, Project Director - Infectious Diseases & Viral Challenge Unit, SGS Life Sciences	**Implementing predictive modelling to improve control on process robustness** Senior representative, Batavia Biosciences
15:50	Technology Showcase 6 **Session to be confirmed**		**Improving process control of virus production using real time analytics** Senior representative, IDT Biologika
16:05	Networking Break		
16:35	**The potential of self-amplifying mRNA vaccines** Dr Jeffrey B. Ulmer, Head, Preclinical R&D US, GSK Vaccines	**Human viral challenge studies: Accelerating drug and vaccine development** Senior representative, hVIVO	**Definition of formulation strategy for vaccines** - Development of formulation process and transfer to GMP department - Support to regulatory file for clinical trials - High throughput formulation methodologies to de-risk manufacture, formulation design, and clinical progression
17:05	**Design of a CMV vaccine capable of eliciting both arms of adaptive immunity**	**Future of adjuvants – what is needed? Better strategy for a rational design**	**Lessons learnt on producing and purifying over thirty different VLP´s for a universal influenza vaccine** Dr Antonio Roldao, Senior Researcher, iBET
17:35	**Using VLP technology to develop a Norovirus vaccine candidate**	**Correlates of protection: The ability to establish what they are and what they can test**	**Building a reliable fill-finish infrastructure to support pre-clinical batches and final finished product/dosage forms**

	- Results of clinical Phase I and II data - Evidence of benefits over live and other challenge models	**Key factors for success in publishing vaccine clinical trials** Anne Hepburn, Director, Scientific Writing and Regulatory Affairs, 4Clinics	
18:05	Chair's closing remarks and close of day two followed by **Meet & Greet with key speakers**		

worldvaccine CONGRESS 2016

Day 3 agenda 12th October 2016

	Clinical Development in Vaccines to address AMR	Vaccine Delivery	Manufacturing
09:15	Chair's opening remarks Dr Jan T Poolman, Head Bacterial Vaccine Discovery and Early Development, Janssen	Chair's opening remarks	Chair's opening remarks Dr Antu K. Dey, Senior Director, Research & Development, International AIDS Vaccine Initiative
09:20	Epidemiology: How big is the problem of AMR? Prof Marc Bonten, Co-chairman of the Infection and Immunity research program, UMC Utrecht*	Vaccine delivery technologies that provide muscosal and systemic immunity Dr Derek O'Hagan, Global Head of Vaccine Chemistry and Formulation Research, GSK	To what extent are disposable technologies a better choice for rapid and effective delivery of vaccines Senior representative, Pall
09:50	Bacterial paediatric vaccine overview: Using bacterial vaccines for AMR vaccines Dr Jan T Poolman, Head Bacterial Vaccine Discovery and Early Development, Janssen	How physico-chemical properties of liposomes, emulsions, antigens and different routes of delivery can influence the immunological outcome - Vaccine delivery – what role does it play? - Depot or not? Dr Dennis Christensen, Head of section, Vaccine Research & Development , Infectious Disease Immunology, Statens Serum Institut	Bioreactor needs for the developing world: Vaccine self-sufficiency and pandemic outbreaks XL Lin, Founder, President & CEO, VacciXcell a member of Esco Group of companies
10:20	Results from a TB vaccine entering a large phII study in newborns from HIV positive mothers Prof Stefan Kaufmann, Founding Director and Managing Director of the Max Planck Institute for Infection Biology	Laser-assisted technology for epidermal delivery of immunogens in a cancer vaccine setting	Accelerating the development and manufacturing of Vaccines in critical situations: Case studies & perspectives Dr Anissa Boumlic-Courtade, Europe Vaccine Market lead Life Science, Process Solutions, Merck
10:50	Networking Break		
11:30	Extraintestinal pathogenic *Escherichia coli*, a common human pathogen: Challenges for vaccine	The future of virosome development for vaccine delivery	Application of QbD to vaccine development

For 2016 speaking opportunities please contact the Project Manager, Wing-yun Cheung on: wing-yun.cheung@terrapinn.com or on + 44 (0)207 7092 1172

	development and progress in the field Dr Peter Hermans, Senior Scientific Director, Janssen		- Critical Quality Attributes - identification and acceptance ranges - Analytical Control Strategy - Process Understanding Dr Cristiana Campa, Head, Quality by Design Integration, GSK Vaccines
11:50	The clinical path to successful licensure of pneumococcal and MenB vaccines Dr Annaliesa Anderson, Vice President and CSO Bacterial Vaccines, Pfizer*	What are the analytical challenges between traditional freeze dry formulations and patches? - Stability, dose and immunogenicity in skin patched vaccines	Incorporating big data and analytics into the vaccine manufacturing process to optimize yields
12.10	A vaccine approach to the prevention of symptomatic C.diff Dr Patricia Pietrobon, Associate Vice President, R&D, Cdiff Program Leader, Sanofi Pasteur*	Optimising intradermal injection for high-value and emerging market vaccines	Continuous manufacturing: Connecting process development and facility design for capital efficiency
12:30	Networking Lunch		
	Plenary Session		
13.30	Chair's opening remarks		
13:35	Justifying maternal immunization: Where are we with development of vaccines that affect maternal and infant health? - Policy, products and regulatory Requirements - Developments and results from clinical trials and vaccination rates - Ethical considerations and business sustainability Thomas Breuer, SVP & Chief Medical Officer, GSK Vaccines		
14:05	Interactive discussion: Is the eradication of Measles and containment of the virus possible? A scientific and political matter - Progress toward measles elimination - different aspects of global policy and challenges to measles vaccination - What happens after eradication? - Will similar viruses take over? - Preparation strategies Prof Albert Osterhaus, Director Research Center for Emerging Infections and Zoonoses (RIZ), University of Veterinary Medicine Hannover Dr James L. Goodson, Senior Measles Scientist, Accelerated Disease Control and VPD Surveillance Branch, Global Immunization Division, Center for Global Health, CDC*		
14:50	Interactive discussion: Access to vaccines - Ensuring resilience of high quality vaccine supply - What are the key long term risks to resilience of vaccine supply - How should manufacturers, regulators and government work together to build resilience into the global supply of high quality vaccines? - How might new production technologies and regulatory approaches be harnessed to dealing with fluctuating demand and generally increase resilience? Dr Stephen Inglis, Director, NIBSC Heather Deehan, Chief, Vaccine Centre, UNICEF Supply Division		

	Dr Suresh Jadhav, Executive Director, Serum Institute of India Thomas Breuer, SVP & Chief Medical Officer, GSK Vaccines Dr Anders Vinther, Chief Quality Officer, Sanofi Pasteur
15:50	Chair's closing remarks and close of Congress

**Speakers subject to final session confirmation*

immuneprofiling
WORLD CONGRESS 2016

immuneprofiling WORLD CONGRESS 2016

Co-located with:

worldvaccine CONGRESS 2016

Immune Profiling in Infectious and Non-infectious Diseases

Congress Agenda

Learn. Discover. Network.

11 – 12th October, Fairmont Rey Juan Carlos, Barcelona

http://www.fairmont.com/barcelona/

With newer and more advanced immune profiling technologies, we are getting to understand the human immune system more and more. From infection, vaccination to how disease or pathogens alters immune cell repertoires and their functional activities. This congress brings together experts to discuss how profiling of the immune system using high throughput technologies, can aid therapeutic design and treatment strategies in infectious and non-infectious diseases.

For 2016 speaking opportunities please contact the Project Manager, Wing-yun Cheung on:
wing-yun.cheung@terrapinn.com or on + 44 (0)207 7092 1172

Day 1 agenda - 11 October 2016

09:00	**Chair's opening remarks**
Characterisation of the immune response	
09:05	**The dual role of biomarkers for understanding basic principles and devising novel intervention strategies in tuberculosis** - Using high-throughput analyses, such as transcriptomic and metabolic profiling to develop clinically useful biosignatures - Gaining a better understanding of the disease process and predict onset of disease - Biomarkers based on cytokine composition provide important insights into the basic biological principles of TB and give an opportunity to reliably distinguish TB patients from healthy individuals Prof Stefan Kaufmann, Founding Director and Managing Director of the Max Planck Institute for Infection Biology
09:35	**Analysis of the immune system during HIV infection** - Cellular immunity to HIV - Using biosystems approaches to define immune parameters of HIV control - Identifying predictors of vaccination outcome Dr Christian Brander, Research Professor, IrsiCaixa & Scientific Director, HIVACAT
10:05	**Optimized immune profiling by understanding T-cell and B-cell repertories during cancer** - Categorising T-cell diversity to cancer and disease - A high-throughput method for sequencing and quantification of rearranged antigen receptors on T- and B-cells - Functional genomics and genetics
Biomarkers and surrogate markers of vaccine efficacy and safety	
10.35	**Signatures and ink spots of vaccine induced responses** - From surrogate markers to predictive biomarkers of vaccine efficacy - How realistic is it to enhance the blood markers beyond serum antibody? Dr Ali Harandi, Associate Professor, Lab head, University of Gothenburg
11:00	**Morning networking break**
12:00	**Skin immunity for vaccination using omics to better describe the innate immunity and to predict the adaptive immunity** Dr Behazine Combadiere, Director of Research DR2, INSERM
12:30	**Systems integration of innate and adaptive immunity: Implications for vaccine development** - Using computational tools to predict adaptive immunity - Examples from RTSS malaria vaccine with GSK - Finding other related pathways to test immunogenicity - Hypothesise activities of adjuvants and biomarkers Dr Daniel Zak, Assistant Professor, The Center for Infectious Disease Research
13:00	**Networking Lunch & Poster Session**
Immunosequencing and high throughput analysis	
14:35	**Predictive & Precision medicine: Diagnostic testing, biomarkers and immunoassay systems** - Better ways to predict, characterize, and tailor diagnostic, prognostic, and therapeutic opportunities for patients.
15:05	**Rapidly screening a novel affinity scaffold library for PD-L1 Inhibitors** - High throughput protein expression capabilities - Identifying multiple clones that inhibit PD-L1/PD1 interaction enabling further investigation of these as biotherapeutics leads

For 2016 speaking opportunities please contact the Project Manager, Wing-yun Cheung on: wing-yun.cheung@terrapinn.com or on + 44 (0)207 7092 1172

15:35	**Immunosequencing: Combining high-throughput sequencing and bioinformatics to profile T-cell and B-cell receptors** - Translating immunosequencing discoveries into clinical diagnostics and therapeutic development
16:05	**Afternoon break**
16:35	**Single-cell technologies: Validating discoveries and translating them into clinically useful diagnostic assays** - Enabling the identification and generation of functional human antibodies and TCRs without prior knowledge of antigen
17:05	**Utilising next generation sequencing for fast and accurate processing of sequencing data from T- and B- cell receptor libraries** - How has next-generation sequencing revolutionized the characterization of human immune responses? - Identifying immunogenic mutations – Will these need to be patient specific to get meaningful antigens?
17:35	**Developing novel antibody immunotherapies that help the immune system attack diseased cells** - Studying rare immune cells at high resolution - Measuring drug effects in a patient-specific, disease-specific manner - Understanding broadly how immunotherapy works in humans, based on its ability to evaluate the function of critical rare immune cells in human clinical samples
18:05	Chair's closing remarks and close of day two followed by **Meet & Greet with key speakers**

Day 2 agenda - 12 October 2016

09:15	**Chair's opening remarks**
Immuno-oncology approaches	
09:20	**Discussing the role of checkpoint inhibitors in the context of a broader immuno-oncology strategy** - Treating cancer by targeted activation of the immune system - Dissecting antigen-specific T cell immunity in human cancer - Reviewing toxicity profiles of checkpoint blockade and dual checkpoint blockade - Patient selection on PDL-1 and 2 status - Use of novel biomarkers and exciting combinations Dr Roy Baynes, Senior Vice President Global Clinical Development, MSD
09:50	**Identifying solutions to improve the efficacy of PD-1 and CTLA-4** - Disabling the function of immune checkpoint molecules can unlock T-cell immunity against cancer - Explaining possible causes of resistance that is essentially unexplained
10:20	**Next generation of immune checkpoint inhibitors** - Lessons learnt from regulatory challenges encountered in the development of checkpoint inhibitor immunotherapy - Investigate strategies to validate novel checkpoint pathways and the potential of novel targets and combination with active immunization - Impact on the future of the immune checkpoint inhibitor field
10:50	**Morning networking break**
11:30	**Insights from Listeria monocytogenes for the development of vector- and small molecule-based cancer immunotherapy strategies**

	- Modulating the tumour microenvironment and priming for tumour-specific immunity - Inducing a systemic pro-inflammatory cytokine profile and facilitating immune recognition - Evaluation of the impact of CRS-207/GVAX in combination with PD-1 blockade on survival in patients with metastatic pancreatic cancer Dr Thomas W. Dubensky, Chief Scientific Officer, Aduro Biotech
11:45	Direct identification of neo-epitopes for cancer vaccines and adoptive T-Cell therapies - Review of published data showing that mutations drive protective T cell response in cancer - Importance of neoantigen selection - Clinical applications Dr James Noble, Chief Executive Officer, Adaptimmune – *session to be finalised*
12:00	Next-generation biomarkers for the era of combination cancer immunotherapy - Translational research and biomarker approaches to address combination therapy approaches in immune-oncology
12:30	Networking lunch
13:30	Immunoscore®: An innovative combination of immunohistochemistry and digital pathology-based scoring - Assessing multiple immune-related biomarkers currently under investigation - Promising candidates for predicting patient response to immuno-oncology treatments in several solid tumours Dr Jerome Galon, Research Director, Chief, Inserm Laboratory
14:00	Next generation CAR Technology: Amplifying the immune response within the tumour microenvironment - Using CAR T-cell therapy for optimal anti-cancer treatment - Future challenges for the CAR T-cell approach and combinations with other cancer treatments and vaccines Prof Zelig Eshhar, Professor, Chemical & Cellular Immunology, Weizmann Institute of Science
14:30	Promising Phase II results in treatment of chemotherapy refractory colorectal and pancreatic patients in monotherapy clinical trial: A patient to lab approach - Support and plans for Phase III trials - Identifying various combination therapies and immune correlates - Application's with new technologies including antibody drug conjugates (ADC), CAR T-cell, Bi-specific t-cell engagers (BiTEs) antibody Dr Philip M. Arlen, President & Chief Executive Officer, Precision Biologics, Inc.
15:00	Oncolytic viruses: a new class of immunotherapy drugs - Promoting anti-tumour responses through a dual mechanism of action that is dependent on selective tumour cell killing and the induction of systemic anti-tumour immunity - Unique challenges in the development of oncolytic viruses as a new class of drugs for the treatment of cancer Dr Ronald Herbst, VP of Oncology Research, Medimmune
15:30	Chair's closing remarks and close of congress

worldveterinary VACCINE CONGRESS 2016

Co-located with:

worldvaccine CONGRESS 2016

Congress Agenda

Learn. Discover. Network.

11 – 12th October, Fairmont Rey Juan Carlos, Barcelona

http://www.fairmont.com/barcelona/

The 2nd annual World Veterinary Vaccine Congress is the place where the global vaccine industry meets to discuss commercial and scientific issues around **new technology**, **regulation, manufacturing** and **vaccine development** as well as **respiratory, cancer and emerging diseases** areas that link animal and human health together. For more information please visit http://www.terrapinn.com/conference/world-veterinary-vaccine-congress/

In collaboration with:



For 2016 speaking opportunities please contact the Project Manager, Wing-yun Cheung on:
wing-yun.cheung@terrapinn.com or on + 44 (0)207 7092 1172

Our Scientific Advisory Board

Prof Albert Osterhaus, Director Research Center for Emerging Infections and Zoonoses (RIZ), **University of Veterinary Medicine Hannover**

Dr Mahesh Kumar**, Vice President, Global Biologics Research,** Zoetis

Dr Nathalie Garcon, **CEO/CSO**, BIOASTER

Prof Manuel J T Carrondo, **Vice-President**, IBET

World Veterinary Vaccines Congress Agenda

Pre-Congress Workshop - 10 October 2016

	How to choose which platform is most suitable to develop a new vaccine for an emerging disease
14:45	Welcoming address
14:50	New vaccines are all moving away from traditional vaccine approaches so how do we choose one platform over another? What are the range of viruses that we need to be ready for? The threat of the Zika virus Prof Albert Osterhaus, Director Research Center for Emerging Infections and Zoonoses (RIZ), University of Veterinary Medicine Hannover Review of different viral and bacterial vector delivery systems Dr Jean-Christophe Audonnet, ZAPI Project Coordinator, Merial Dr Edmond Jolivet, Head of Molecular Bacteriology laboratory, Merial The success of DNA vaccines to the animal health arena How far are we from commercializing nanoparticle technology? Pox virus based platforms *More speakers to be announced shortly*
16:15	Networking break
16:45	Round table discussions to discuss pros and cons of selected platforms How do we ensure that these technologies make it to the market? Considerations to regulatory hurdles, scalability, manufacture and cost
17:15	Presentation of conclusions by discussion leaders
17:45	End of workshop

Day 1 agenda - 11 October 2016

09:00	Chair's opening remarks
Bringing together human and animal vaccines	
09:05	Where is the veterinary vaccines industry heading? - The journey of developing Bovela - Consolidation of the industry - Threat of emerging and infectious diseases to animal and human health Dr Randolph Seidler, Managing Director, Global Head of R&D Animal Health, Boehringer Ingelheim Veterinary Research Center
09:35	One Health: Efforts made around emerging and food borne pathogens - What reasonable guidelines should we all follow? - Blurring the lines between human and animal health

For 2016 speaking opportunities please contact the Project Manager, Wing-yun Cheung on: wing-yun.cheung@terrapinn.com or on + 44 (0)207 7092 1172

<table>
<tr><td></td><td colspan="4">- The dramatic food safety potential in using vaccines
Dr Arvind Mahajan, Director Research and Development, Elanco</td></tr>
<tr><td>10:05</td><td colspan="4">Developing clinical model to support vaccines research and development
- Clinical models that can test vaccine efficacy in different situations, examples in swine
- Gaining better insights from animals models that could be applicable to human vaccine development like MERS
Dr Joaquim Segalés, Director, Centre de Recerca en Sanitat Animal (CReSA)</td></tr>
<tr><td>10.35</td><td colspan="4">Bridging the gap between animal and human adjuvanted vaccines
- How can we extrapolate the use of adjuvants in animal and human vaccines to benefit all species
- Measuring efficacy, toxicity and correlates of protection
Dr Nathalie Garcon, CSO/CTO, Bioaster</td></tr>
<tr><td>11:00</td><td colspan="4">Networking break</td></tr>
<tr><td>12:00</td><td colspan="4">Interactive Roundtables
Choose your roundtable session and explore a range of topical issues that can be discussed with other though leaders at a more interactive basis:

To lead a table or for more information on other topics contact the Project Manager Wing-yun Cheung on Wing-yun.Cheung@terrapinn.com</td></tr>
<tr><td></td><td>Promoting a one health research ethos by bringing veterinary and medical scientists together
Prof Albert Osterhaus, Director Research Center for Emerging Infections and Zoonoses (RIZ), University of Veterinary Medicine Hannover</td><td>Assurance of supply of single-use technologies, including a case study about a pandemic situation
Senior representation Sartorius</td><td>Regulatory aspects of adjuvants in manufacturing and use
Dr Adrian Wildfire, Project Director - Infectious Diseases & Viral Challenge Unit, SGS Life Sciences</td><td>What's the global strategy in responding to infectious diseases? Combined efforts and differences between Europe and the US</td></tr>
<tr><td></td><td>The strategy behind developing vaccines against neglected diseases</td><td>Developing improved analytical testing for next-generation vaccines
Dr Cristiana Campa, Head, Quality by Design Integration, GSK Vaccines</td><td>Vaccine delivery: How to increase efficacy of vaccines, and the challenges from moving to therapeutic vaccines versus prophylactic
Kirsty Gapp, M.T.S Business Development Manager, 3M Healthcare</td><td>From surrogate markers to predictive biomarkers of vaccine efficacy: How realistic is it to enhance the blood markers beyond serum antibody?
Dr Ali M. Harandi, Lab head, Dpt of Microbiology & Immunology, University of Gothenburg</td></tr>
<tr><td>13:00</td><td colspan="4">Networking Lunch & Poster Session</td></tr>
<tr><td colspan="5">Incorporating novel vaccinology approaches</td></tr>
</table>

14:35	**Using a systems biology approach to gain a better understanding of immunological responses: Predicting effectiveness to prevent clinical failure** - Identifying molecular signatures of vaccine adjuvants - Predicting the effects of adjuvants early through comparative data
15:05	**Presenting a novel live bacterial adjuvanted vaccine** - R&D challenges in developing a live vaccine - Identifying the right adjuvants and rationale in vaccine design Dr Edmond Jolivet, Head of Molecular Bacteriology laboratory, Merial
15:35	**Advances in RNA vaccines that have revolutionized immunotherapy treatment** - Developing precise protein constructs of interest - Expressing viral antigens in vivo and to induce robust immune responses
16:05	**Afternoon break**
16:35	**When is reverse vaccinology appropriate to use? Future developments of efficacious vaccines** - NGS and reverse vaccinology - Utilization of genotype and phenotype selection - Identifying the best vaccine candidate
16:50	**Technologies to facilitate a rapid vaccine response to newly emerging pathogens** - Identification of protective antigens - Novel adjuvants to increase potency and breadth - Rapid response to newly emerging pathogens Dr Jeffrey B. Ulmer, Head, Preclinical R&D US, GSK Vaccines
17:05	**The role of novel diagnostic methods in protecting both animals and humans** - Using high throughput technologies and marker vaccines to differentiate between vaccinated and infected animals - Understanding the pathogenesis of infectious diseases like Avian Influenza virus (AIV), Bluetongue virus (BTV) and Schmallenberg virus (SBV) to prevent outbreaks
17:35	**Modified replication-deficient viruses as a delivery vector** - Overview and advantages of vaccine delivery platform technology - Current and past animal vaccine development efforts - Future directions and potential hurdles
18:05	Chair's closing remarks and close of day two followed by **Meet & Greet with key speakers**

Day 2 agenda - 12 October 2016

09:15	Chair's opening remarks
Emerging & Re-Emerging Diseases	
09:20	One step closer to developing an effective MERS-CoV vaccine: New camel data - An orthopoxvirus-based vaccine reduces virus excretion after MERS-CoV infection in dromedary camels - Illustrating how a modified vaccinia virus Ankara (MVA) vaccine expressing the MERS-CoV spike protein confers mucosal immunity in dromedary camels - Significantly reducing excreted infectious virus and viral RNA transcripts in vaccinated animals upon MERS-CoV challenge Prof Albert Osterhaus, Director Research Center for Emerging Infections and Zoonoses (RIZ), University of Veterinary Medicine Hannover, Foundation
09:50	Intervention strategies to support the global control and eradication of foot-and-mouth disease virus - How can the industry work together to contribute in a fast response and speed to the market in case of an emerging infectious
10:20	Influenza vaccine candidates based on the pox viral vector MVA Professor Guus Rimmelzwaan, Viroscience lab, Erasmus MC
10:50	Morning networking break
11:30	A one health approach to developing vaccines against bovine tuberculosis - Using animals models that give more clinically meaningful information to human vaccine development, bovine TB - Eradication at the source for human and animal protection - Understanding the epidemiological status – how could the movement of people from the middle east to western Europe (or other external factors) increase the risk of infection? Dr Glyn Hewinson, Chief Scientist, Lead in TB, Animal & Plant Health Agency, UK
11:45	Vaccines for the developing world: Accessibility and affordability - New vaccine formulations for developing world livestock - Responding to emerging infectious disease outbreaks – Rift valley fever Dr Jeremy Salt, Senior director R&D, GALVmed
	The Path to Developing Effective Veterinary Vaccines
12:00	Utilizing a fixed-bed bioreactor as a solution to improve manufacturing capacity and cost of goods for veterinary vaccines Senior representative, Pall
12:30	Networking lunch
13:30	The challenge of Leishmania vaccine development - After 20 years, highlighting the development, registration or clinical challenges of developing a neglected disease vaccine Dr Mercedes Fabra, Project leader, Immunology and Vaccines for Global Health, Laboratorios LETI, S.L.
14:00	Easing vaccination programs through combination - Combined vaccines and separate vaccines that can combined during application (compatibility) - Reducing number of applications to improve animal welfare Dr Rik Koopman , Global Technical Director, Global Poultry Business Unit, MSD Animal Health

14:30	**Under what conditions can GMP standards be modified for veterinary vaccines?** - Understanding what processes/systems suit your vaccine best - Having the regulatory expertise to understand when conditions are amendable
15:00	**Purification strategies that supports greater consistency and higher quality veterinary vaccines** - Maintaining efficient control of veterinary diseases, while allowing production to remain economically competitive - Membrane-based clarification and concentration techniques
15:30	Chair's closing remarks and close of congress